Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Govt Council OKs Draft Policy to Strengthen Vaccine R&D, Establish SCARDA
The government’s pharmaceutical development council approved on February 28 a draft policy to promote vaccine R&D, which includes a plan to establish the “Strategic Center of Biomedical Advanced Research and Development for Preparedness and Response” (SCARDA) tasked with the execution…
To read the full story
Related Article
- Govt Council Calls for Steps to Beef Up Japan’s Clinical Trial System for Vaccines
July 13, 2022
- SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
April 25, 2022
- SCARDA Now Up and Running: Will It Lead to a Recovery in Japan’s Ability to Develop Vaccines?
April 22, 2022
- SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
April 19, 2022
- SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
- Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
April 4, 2022
- AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
March 23, 2022
REGULATORY
- LDP Health Chief Demands CEA Overhaul, Backs Freeze on Price Cuts
October 20, 2026
- Japan Eyes Spring 2027 Plan to Address Drug Discovery Workforce Needs
October 19, 2026
- Minister Lauds Stemirac after Panel Backs Full Approval
October 19, 2026
- CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
October 16, 2026
- Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…